secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001558370-24-002183
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor reports Q4 net loss $0.8M; Phase 3 DMD trial on track for top-line data Q4 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $0.8M ($0.02/share) vs $7.7M ($0.31) in Q4 2022; revenue $12.1M from Nippon Shinyaku agreement.
- Cash $39.5M at Dec 31, 2023; $10M milestone payment from Nippon Shinyaku received Jan 2024.
- Enrollment complete in Cohort A of Phase 3 HOPE-3 trial for CAP-1002 in DMD; positive interim futility analysis.
- Cohort B enrollment underway, expected to complete Q2 2024; top-line data from Cohort A expected Q4 2024.
- Selected for Project NextGen; NIAID to fund Phase 1 trial of StealthX exosome-based COVID-19 vaccine in late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/0001558370-24-002183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/capr-20240229x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer